Literature DB >> 25130432

Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia.

Mansi Arora1, Deepak Kaul2, Neelam Varma3, R K Marwaha4.   

Abstract

There exists a general recognition of the fact that post translational modification of CYLD protein through proteolytic cleavage by MALT-1 results in sustained cellular NF-kB activity which is conspicuously found to be associated with cancer in general and hematological malignancies in particular. The present study was directed to understand the contribution of MALT-1 and deubiquitinase CYLD to the initiation of T-cell acute lymphoblastic leukemia (T-ALL). Such a study revealed for the first time that the 35kDa CYLD cleaved factor generated by MALT-1 mediated proteolytic cleavage was conspicuously present in human T- ALL subjects of pediatric age group. Further, over-expression of this 35kDa CYLD factor within normal human peripheral blood mononuclear cells had the inherent capacity to program the genome of these cells resulting in T-cell lineage ALL. Based upon these results, we propose that MALT1 inhibitors may be of crucial importance in the treatment of T-ALL subjects of pediatric age group.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CYLD cleavage; Human PBMCs; MALT1; Pediatric T-ALL; Transformation

Mesh:

Substances:

Year:  2014        PMID: 25130432     DOI: 10.1016/j.bcmd.2014.07.008

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  8 in total

Review 1.  CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different.

Authors:  Marie Lork; Kelly Verhelst; Rudi Beyaert
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

Review 2.  The Paracaspase MALT1.

Authors:  Janna Hachmann; Guy S Salvesen
Journal:  Biochimie       Date:  2015-09-16       Impact factor: 4.079

3.  CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.

Authors:  Lei Yin; Shuai Liu; Chensheng Li; Sentai Ding; Dongbin Bi; Zhihong Niu; Liping Han; Wenjia Li; Dexuan Gao; Zheng Liu; Jiaju Lu
Journal:  Tumour Biol       Date:  2016-07-22

4.  GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.

Authors:  Jing Cheng; Linda R Klei; Nathaniel E Hubel; Ming Zhang; Rebekka Schairer; Lisa M Maurer; Hanna B Klei; Heejae Kang; Vincent J Concel; Phillip C Delekta; Eric V Dang; Michelle A Mintz; Mathijs Baens; Jason G Cyster; Narayanan Parameswaran; Margot Thome; Peter C Lucas; Linda M McAllister-Lucas
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

5.  CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism.

Authors:  Yunfan Yang; Jie Ran; Lei Sun; Xiaodong Sun; Youguang Luo; Bing Yan; Min Liu; Dengwen Li; Lei Zhang; Gang Bao; Jun Zhou
Journal:  Theranostics       Date:  2015-03-02       Impact factor: 11.556

Review 6.  The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies.

Authors:  Neha Sarodaya; Janardhan Karapurkar; Kye-Seong Kim; Seok-Ho Hong; Suresh Ramakrishna
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

7.  Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.

Authors:  Xin Xu; Ting Wei; Weijie Zhong; Rosalind Ang; Ye Lei; Hui Zhang; Qingshan Li
Journal:  Cancer Cell Int       Date:  2021-04-07       Impact factor: 5.722

8.  High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid.

Authors:  Wei Wu; Huayuan Zhu; Yuan Fu; Wenyi Shen; Kourong Miao; Min Hong; Wei Xu; Lei Fan; Ken H Young; Peng Liu; Jianyong Li
Journal:  Oncotarget       Date:  2016-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.